Vagus Nerve Stimulation (VNS) is a neuromodulation therapy that activates the vagus nerve to modulate neural circuits involved in inflammation, neurotransmitter regulation, and neuroplasticity. Originally developed for epilepsy and later approved for treatment-resistant depression, VNS has emerged as a promising cross-disease therapeutic for neurodegenerative disorders due to its effects on the cholinergic anti-inflammatory pathway and central norepinephrine systems[1].
The vagus nerve exerts anti-inflammatory effects through the cholinergic anti-inflammatory pathway (CAP), a neuroimmune axis that regulates peripheral and central inflammation[2]:
This mechanism is particularly relevant for neurodegenerative diseases where neuroinflammation plays a central pathogenic role.
VNS activates locus coeruleus neurons, the primary source of central norepinephrine (NE)[3]:
| Target | Mechanism | Disease Relevance |
|---|---|---|
| Nucleus tractus solitarius | Primary vagal integration | Autonomic dysregulation in PD |
| Locus coeruleus | NE modulation | Cognitive decline in AD |
| Dorsal raphe | Serotonin modulation | Depression comorbidity |
| Spleen/peripheral immune | Cytokine suppression | Systemic inflammation |
| Microglia | Neuroinflammation reduction | All neurodegenerative diseases |
Surgically implanted devices deliver chronic stimulation to the left vagus nerve:
Non-invasive approaches stimulate vagal afferents through external sites:
A randomized, sham-controlled trial of VNS in mild-to-moderate AD demonstrated[4]:
VNS may enhance effects of existing AD therapies:
Clinical studies have explored VNS for PD motor symptoms[6]:
VNS shows particular promise for PD non-motor symptoms:
VNS has been explored for respiratory dysfunction in ALS[7]:
VNS is FDA-approved for refractory epilepsy[8]:
VNS is FDA-approved for treatment-resistant depression[9]:
Evidence is limited but biologically plausible:
Auricular VNS stimulates the auricular branch of the vagus nerve, which innervates the cymba concha of the external ear[10]:
| Device | Type | FDA Status | Features |
|---|---|---|---|
| NEMOS | aVNS | CE marked | Auricular electrode |
| GammaCore | tcVNS | FDA cleared | Cervical stimulation |
| Parasym | aVNS | CE marked | Non-invasive |
Active and planned trials in neurodegeneration:
Vagus Nerve Stimulation represents a promising cross-disease therapeutic approach for neurodegenerative diseases. Its dual mechanism—cholinergic anti-inflammatory pathway activation and norepinephrine modulation—addresses two core pathological features of neurodegeneration: neuroinflammation and neurotransmitter deficiency. While FDA-approved for epilepsy and depression, growing evidence supports exploration in Alzheimer's disease, Parkinson's disease, and potentially other neurodegenerative conditions. Non-invasive approaches (tVNS, aVNS) offer accessible alternatives with favorable safety profiles, though efficacy data remain more limited than for invasive VNS.
Bonaz, B., et al. (2016). Vagus nerve stimulation: from epilepsy to the cholinergic anti-inflammatory pathway. Neurogastroenterology & Motility. 2016. ↩︎
Tracey, K.J. (2007). Physiology and immunology of the cholinergic antiinflammatory pathway. Journal of Clinical Investigation. 2007. ↩︎
Roosevelt, R.W., et al. (2006). Elevated cortical and subcortical norepinephrine in a rat model of Parkinson's disease: potential role in 6-OHDA-induced deficits. Brain Research. 2006. ↩︎
Merrill, C.A., et al. (2006). Vagus nerve stimulation for patients with mild to moderate Alzheimer's disease: 1-year outcomes. American Journal of Alzheimer's Disease & Other Dementias. 2006. ↩︎
Jiang, Y., et al. (2018). Vagus nerve stimulation improves spatial memory in APP/PS1 mice. Neurobiology of Aging. 2018. ↩︎
Mondal, B., et al. (2019). Vagus nerve stimulation for Parkinson's disease: a systematic review and meta-analysis. Journal of Movement Disorders. 2019. ↩︎
Howson, P.A., et al. (2018). Vagus nerve stimulation in amyotrophic lateral sclerosis: safety and efficacy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018. ↩︎
Ben-Menachem, E. (2002). Vagus nerve stimulation, side effects, and long-term safety. Journal of Clinical Neurophysiology. 2002. ↩︎
Rush, A.J., et al. (2005). Effects of chronic vagus nerve stimulation on treatment-emergent suicidal ideation: a randomized, controlled trial. Journal of Clinical Psychiatry. 2005. ↩︎
Pečar, J., et al. (2022). Transcutaneous vagus nerve stimulation: from control of seizures to emerging applications in Alzheimer's disease. Frontiers in Neuroscience. 2022. ↩︎